Equities analysts expect XOMA Corp (NASDAQ:XOMA) to announce earnings per share (EPS) of ($0.38) for the current fiscal quarter, according to Zacks. Two analysts have made estimates for XOMA’s earnings, with the lowest EPS estimate coming in at ($0.40) and the highest estimate coming in at ($0.35). XOMA reported earnings of $1.98 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 119.2%. The firm is scheduled to issue its next earnings report on Monday, November 5th.

According to Zacks, analysts expect that XOMA will report full-year earnings of ($1.14) per share for the current financial year, with EPS estimates ranging from ($1.42) to ($0.70). For the next year, analysts expect that the business will post earnings of ($0.82) per share, with EPS estimates ranging from ($1.37) to ($0.44). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover XOMA.

XOMA (NASDAQ:XOMA) last released its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.03). XOMA had a return on equity of 379.39% and a net margin of 43.55%. The business had revenue of $2.26 million for the quarter, compared to analysts’ expectations of $4.57 million.

XOMA has been the topic of several recent analyst reports. Wedbush reiterated an “outperform” rating and set a $33.00 target price on shares of XOMA in a research report on Wednesday, August 8th. HC Wainwright reiterated a “buy” rating and set a $49.00 target price on shares of XOMA in a research report on Friday, September 21st. Zacks Investment Research downgraded XOMA from a “buy” rating to a “hold” rating in a research report on Saturday, July 21st. ValuEngine downgraded XOMA from a “hold” rating to a “sell” rating in a research report on Friday, September 7th. Finally, S&P Equity Research reduced their target price on XOMA from $18.74 to $16.26 in a research report on Tuesday, August 14th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $31.32.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its stake in XOMA by 151.6% during the second quarter. BlackRock Inc. now owns 448,856 shares of the biotechnology company’s stock worth $9,373,000 after acquiring an additional 270,437 shares during the last quarter. Acadian Asset Management LLC increased its stake in XOMA by 70.4% during the second quarter. Acadian Asset Management LLC now owns 96,051 shares of the biotechnology company’s stock worth $2,006,000 after acquiring an additional 39,672 shares during the last quarter. Northern Trust Corp increased its stake in XOMA by 308.6% during the second quarter. Northern Trust Corp now owns 68,200 shares of the biotechnology company’s stock worth $1,424,000 after acquiring an additional 51,510 shares during the last quarter. Spark Investment Management LLC increased its stake in XOMA by 16.6% during the second quarter. Spark Investment Management LLC now owns 52,100 shares of the biotechnology company’s stock worth $1,087,000 after acquiring an additional 7,400 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of XOMA by 50.7% in the second quarter. Bank of New York Mellon Corp now owns 35,661 shares of the biotechnology company’s stock valued at $745,000 after buying an additional 12,002 shares in the last quarter. Hedge funds and other institutional investors own 43.60% of the company’s stock.

NASDAQ XOMA opened at $15.30 on Friday. XOMA has a twelve month low of $14.61 and a twelve month high of $37.25. The stock has a market cap of $147.36 million, a P/E ratio of 15.61 and a beta of 2.51. The company has a current ratio of 12.46, a quick ratio of 12.46 and a debt-to-equity ratio of 3.06.

XOMA Company Profile

XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.

Further Reading: Treasury Bonds

Get a free copy of the Zacks research report on XOMA (XOMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for XOMA (NASDAQ:XOMA)

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.